Lifestyle Modifications for the Treatment of Sarcopenic Obesity

Improving Body Composition, Strength, Function and Health Related Quality of Life in Older Individuals With Sarcopenic Obesity Through Lifestyle Modifications

This study evaluates the addition of a high-protein energy-restricted diet to exercise in the treatment of sarcopenic obesity in people aged 65 and over. Half of participants will follow a hypocaloric (500 kcal deficit) high-protein (1.2 -1.5 g Protein/ kg bodyweight) diet alongside an exercise regime, while the other half will follow the same exercise regime alongside their habitual diet . All participants will consume a Vitamin D3 tablet (25micrograms) 3 times a week to achieve a weekly intake of 75 micrograms. Total duration of the intervention will be 16 weeks.

Study Overview

• Status: Unknown
• Conditions: Obesity; Sarcopenia; Sarcopenic Obesity
• Intervention / Treatment: Dietary supplement: Protein Drink/Diet; Behavioral: Exercise; Dietary supplement: Vitamin D3

Detailed Description

Sarcopenic Obesity is associated with advanced ageing and is characterised by increased adipose tissue and loss of muscle mass, strength and/or function. The combination of sarcopenia and obesity can predispose older individuals to more functional disabilities than either of these two conditions alone, leading eventually to increased rates of morbidity and mortality. Lifestyle interventions focusing on physical activity and diet have been suggested as an effective tackling strategy. However, there is limited evidence on the efficacy of such interventions in sarcopenic obese individuals over 65 years of age. Therefore, the aim of this study is to assess the impact of a high protein energy-restriction diet and a mixed exercise program on body composition, strength, functionality and quality of life in older people with sarcopenic obesity.

This is a prospective randomised control trial among independent living sarcopenic obese community-dwellers. Eligible participants are people over 65y who experience increased adiposity (% body fat >28% in men and >40% in women) and low skeletal muscle index (SMI <10.75 kg/m2 in men and <6.75kg/m2 in women). Fifty (50) participants will be randomly allocated to either the exercise group (EX) or the exercise plus high protein energy-restricted diet group (EXD). Each group will undergo 3 exercise sessions/ week for a period of 16 weeks. The exercise sessions will be similar for both groups and will incorporate aerobic, resistance, balance and flexibility elements. The EXD group will receive a 500kcal-deficit diet plan and a milk-based protein supplement (ProMilk 50 by Myprotein; 50 g milk protein/ 500 ml bottle) to consume every day (at post-workout on exercise days or as a pre-bed snack on non-exercising days). The protein consumption will be in the range of 1.2-1.5 g.kg bw-1. A total weekly dose of 75mcg Vitamin D3 (3 x 25mcg) will be administered orally to all participants to avoid potential confounders associated with Vitamin D deficiency/hypovitaminosis. The primary and secondary outcomes will be evaluated at baseline, week 10 and week 16.

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Musselburgh, United Kingdom, EH21 6UU
    • Queen Margaret University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Independent living community-dwellers
• Sarcopenic
• Obese
• Montreal Cognitive Assessment test (MoCA) score > or = 26

Exclusion Criteria:

• Use of pacemaker
• Lactose intolerance
• Parkinson's disease
• Unmanaged pain
• Severe osteoporosis or arthritis
• Use of corticosteroids
• History of pulmonary embolus or myocardial infarction within the previous 2 years
• Heart disease
• Chronic obstructive pulmonary disease
• Chronic kidney disease
• Hypertension (resting systolic pressure >200mmHg, resting diastolic >100mmHg)
• Acute systemic illnesses
• Any other uncontrolled physical, psychological or mental condition that either prohibits adherence to the study protocol or increases significantly the health risks for the subject.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Exercise & Protein Drink/Diet; High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.	Dietary supplement: Protein Drink/Diet; 1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.; Behavioral: Exercise; Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.; Dietary supplement: Vitamin D3; 1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
Active Comparator: Exercise; A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.	Behavioral: Exercise; Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.; Dietary supplement: Vitamin D3; 1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Skeletal muscle mass	Assess changes in total skeletal muscle mass (in kilograms) using bioelectrical impedance analysis at baseline, week 10 and week 16.	Baseline, 10 weeks, 16 weeks
Body fat mass	Assess changes in body fat mass (in kg) using bioelectrical impedance analysis at baseline, week 10 and week 16.	Baseline, 10 weeks, 16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Physical Performance	Assess changes in Physical performance using the Short Physical Performance Battery test (SPPB) with a maximum score of 12.	Baseline, 10 weeks, 16 weeks
Dynamic Balance	Assess changes in dynamic balance using the 1-Arm Reach test (measured in cm).	Baseline, 10 weeks, 16 weeks
Functional Mobility	Assess changes in functional mobility using the timed (in seconds) Get Up-and-go test for 6 meters.	Baseline, 10 weeks, 16 weeks
Health related quality of life	Assess changes in health related quality of life using the Rand SF-36 questionnaire.	Baseline, 16 weeks
Central adiposity	Assess changes in central adiposity by measuring the Sagittal Abdominal Diameter (in cm)	Baseline, 10 weeks, 16 weeks
Handgrip strength	Assess changes in handgrip strength (in kg) using a handgrip dynamometer	Baseline, 10 weeks, 16 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dietary intake	Assess changes in dietary intakes using 3-day recorded diet diaries from baseline to week 16	Baseline, 16 weeks
Serum vitamin D (25-OH) levels	Assess changes in serum vitamin D levels at baseline and week 16	Baseline, 16 weeks

Collaborators and Investigators

• Sponsor: Queen Margaret University
• Collaborators: University of Birmingham
• Investigators: Study Director: Elaine Bannerman, PhD, Queen Margaret University

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Anticipated): June 1, 2016
• Study Completion (Anticipated): September 1, 2016

Study Registration Dates

• First Submitted: February 27, 2015
• First Submitted That Met QC Criteria: February 27, 2015
• First Posted (Estimate): March 4, 2015

Study Record Updates

• Last Update Posted (Estimate): April 5, 2016
• Last Update Submitted That Met QC Criteria: April 2, 2016
• Last Verified: April 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Overnutrition; Nutrition Disorders; Overweight; Body Weight; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Obesity; Sarcopenia; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol
• Other Study ID Numbers: QueenMU